Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medipal Holdings's gross profit for the
three
months ended in Mar. 2026 was $391 Mil. Medipal Holdings's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was $1,723 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Medipal Holdings's gross profit for the
three
months ended in Mar. 2026 was $391 Mil. Medipal Holdings's Revenue for the
three
months ended in Mar. 2026 was $5,708 Mil. Therefore, Medipal Holdings's Gross Margin % for the quarter that ended in Mar. 2026 was 6.84%.
Medipal Holdings had a gross margin of 6.84% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
During the past 13 years, the highestGross Margin % of Medipal Holdings was 7.31%. The lowest was 6.61%. And the median was 6.95%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Medipal Holdings had a gross margin of 6.84% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Medipal Holdings Gross Profit Related Terms
Medipal Holdings Gross Profit Historical Data
* Premium members only.
The historical data trend for Medipal Holdings's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Medipal Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medipal Holdings Gross Profit vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medipal Holdings's Gross Profit distribution charts can be found below:
* The bar in red indicates where Medipal Holdings's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,723 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Medipal Holdings (MEPDF) has a Gross Profit of $1,723 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Medipal Holdings and its competitors.
Is Medipal Holdings' Gross Profit too high?
Medipal Holdings' current Gross Profit is $1,723 Mil. Overall, Medipal Holdings has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' Gross Profit compare to MCK and COR?
Medipal Holdings' Gross Profit of $1,723 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Distribution company?
A good Gross Profit depends on the Medical Distribution industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Medipal Holdings and its competitors. Medipal Holdings's current Gross Profit is $1,723 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Medipal Holdings (MEPDF) has a current Gross Profit of $1,723 Mil. The stock's GF Value™ is $17.73, compared to a current price of $18.35 — trading 3.5% above its estimated fair value. The current Gross Profit is $1,723 Mil. Medipal Holdings' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Medipal Holdings (MEPDF), the current Gross Profit is $1,723 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (MEPDF) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued.
The current stock price of $18.35 is trading 3.5% above its estimated GF Value™ of $17.73.
Key valuation signals for MEPDF:
Gross Profit: $1,723 Mil
GF Value™: $17.73 vs. price of $18.35 (3.5% above fair value)
No single metric tells the full story. See the MEPDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
81GF Score
Get the complete analysis for MEPDF
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEPDF has been successfully added to your 
